Patents Assigned to Orphagen Pharmaceuticals
  • Modulators of retinoid-related orphan receptor gamma
    Patent number: 9657053
    Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: May 23, 2017
    Assignee: ORPHAGEN PHARMACEUTICALS
    Inventors: Scott Thacher, Xiaolin Li, Robert Babine, Bruno Tse
  • MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA
    Publication number: 20130150333
    Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
    Type: Application
    Filed: February 13, 2013
    Publication date: June 13, 2013
    Applicant: ORPHAGEN PHARMACEUTICALS
    Inventor: Orphagen Pharmaceuticals
  • Modulators of retinoid-related orphan receptor gamma
    Patent number: 8389739
    Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: March 5, 2013
    Assignee: Orphagen Pharmaceuticals
    Inventors: Scott Thacher, Xiaolin Li, Robert Babine, Bruno Tse